Abstract
Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.
| Original language | English |
|---|---|
| Pages (from-to) | 188-190 |
| Number of pages | 3 |
| Journal | Cancer Chemotherapy and Pharmacology |
| Volume | 35 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1995 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Erythromycin
- Interaction
- Vinblastine
Fingerprint
Dive into the research topics of 'Vinblastine and erythromycin: an unrecognized serious drug interaction'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver